Pharmacokinetic and metabolic investigation of topiramate disposition in healthy subjects in the absence and in the presence of enzyme induction by carbamazepine

Epilepsia

Volumn 46, Issue 3, 2005, Pages 378-384

  Britzi, Malka ^a,b   Perucca, Emilio ^c   Soback, Stefan ^b   Levy, René H ^d   Fattore, Cinzia ^c   Crema, Francesca ^c   Gatti, Giuliana ^c   Doose, Dennis R ^e   Maryanoff, Bruce E ^e,f   Bialer, Meir ^a,g  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KIMRON VETERINARY INSTITUTE   (Israel)

^c UNIVERSITY OF PAVIA   (Italy)

^d UNIVERSITY OF WASHINGTON   (United States)

^e JOHNSON AND JOHNSON   (United States)

^f Johnson Johnson P   (United States)

^g HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Carbamazepine; Drug interaction; Enzyme induction; Healthy subjects; Metabolism; Pharmacokinetics; Topiramate

Indexed keywords

10 HYDROXYTOPIRAMATE; 2,3 DIOL TOPIRAMATE; 4,5 DIOL TOPIRAMATE; 9 HYDROXYTOPIRAMATE; CARBAMAZEPINE; DRUG METABOLITE; TOPIRAMATE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INDUCTION; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOMNOLENCE; STATISTICAL SIGNIFICANCE; TASTE DISORDER; URINALYSIS; URINARY EXCRETION;

ADULT; ANTICONVULSANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; CHROMATOGRAPHY, LIQUID; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG MONITORING; ENZYME INDUCTION; EQUIPMENT DESIGN; FRUCTOSE; HALF-LIFE; HUMANS; MALE; MASS SPECTROMETRY; METABOLIC CLEARANCE RATE; MIDDLE AGED; TISSUE DISTRIBUTION;

EID: 20144373179     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0013-9580.2005.55204.x     Document Type: Article

References (28)

1. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fund Clin Pharmacol 2001; 15:405-17.
2. Privitera MD, Twyman RE. Topiramate: clinical efficacy and use in epilepsy. In: Levy RH, Mattson RH, Meldrum BS, et al. eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:740-52.
3. Kamin M. Topiramate: clinical efficacy and use in nonepileptic disorders. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:753-9.
4. Bialer M, Johannessen SI, Kupferberg HJT, et al. Progress report on new antiepileptic drugs: a summary of the Seventh Eilat conference on new antiepileptic drugs (EILAT VII). Epilepsy Res 2004;61:1-48.
5. Doose DR, Streeter AJ. Topiramate: chemistry, biotransformation and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al. eds. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins, 2002:727-34.
6. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia 2000;41(suppl):S61-5.
7. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate: a novel antiepileptic drug. J Clin Pharmacol 1996;36:884-91.
8. Nayak RK, Gisclon LG, Curtin CA, et al. Estimation of the absolute bioavailability of topiramate in humans without intravenous data. J Clin Pharmacol 1994;34:1029.
9. Wu WN, McKown LA. Recent advances in biotransformation of CNS and cardiovascular agents. Curr Drug Metab 2000;1:255-70.
10. Sachdeo RC, Sachdeo SK, Walker SA, et al. Steady-state pharmacokinetics of topiramate and carbamazepine in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia 1996;37:774-80.
11. Sachdeo RC, Sachdeo SK, Levy RH, et al. Topiramate and phenytoin pharmacokinetics during repetitive monotherapy and combination therapy to epileptic patients. Epilepsia 2002;43:691-6.
12. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004;43:763-80.
13. Britzi M, Soback S, Isoherranen N, et al. Analysis of topiramate and its metabolites in plasma and urine of healthy subjects and patients with epilepsy by use of a novel liquid chromatography-mass spectrometry assay. Ther Drug Monit 2003; 25:314-22.
14. Miceli JJ, Anziano RJ, Robarge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000;49(suppl 1):65S-70S.
15. Perucca E, Grimaldi R, Frigo GM, et al. Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects. Eur J Clin Pharmacol 1988;34:595-9.
16. Spina E, Avenoso A, Campo GM, et al. The effect of carbamazepine on the 2-hydroxylation of desipramine. Psychopharmacology 1995;117:413-6.
17. Giaccone M, Bartoli A, Gatti G, et al. Effect of enzyme inducing anticonvulsants on ethosuximide pharmacokinetics in epileptic patients. Br J Clin Pharmacol 1996;41:575-9.
18. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetics of oxcarbazepine and its active metabolite 10-hydroxy-carbazepine in healthy subjects and in epileptic patients treated with phenobarbitone or valproic acid. Br J Clin Pharmacol 1993;36:366-8.
19. Yamaoka K, Nakagawa T, Uno T. Statistical moments in pharmacokinetics. J Pharmacokinet Biopharm 1978;6:547-58.
20. Gibaldi M, Perrier D. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982.
21. Rowland M, Tozer T. Clinical Pharmacokinetics, 3rd ed. Baltimore: Williams & Wilkins, 1995.
22. Nortey SO, Wu W-N, Maryanoff BE. Synthesis of hydroxylated derivatives of topiramate: a novel antiepileptic drug based on D-fructose: investigation of oxidative metabolites. Carbohydr Res 1997;304:29-38.
23. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age and comedication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003;25:700-8.
24. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet (in press).
25. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600 mg daily dosages. Neurology 1996;46:1684-90.
26. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004;26:251-7.
27. Contin M, Riva R, Albani F, et al. Topiramate therapeutic monitoring in patients with epilepsy: effect of concomitant antiepileptic drugs. Ther Drug Monit 2002;24:332-7.
28. Maryanoff BE, Nortey SO, Gardocki JF, et al. Anticonvulsant O-alkylsulfamates.2,3:4,5-bis-O-(1-methylethlidene)-β-D-fructopyranose- sulfamate and related compounds. J Med Chem 1987;30:880-7.